Novartis Receives FDA Approval of Menveo(R), a Vaccine to Prevent Meningococcal Disease

Monday, February 22, 2010 Drug News
Email Print This Page Comment bookmark
Font : A-A+

- Menveo licensed in 11-55 year olds to help protect against potentially deadly meningitis and sepsis caused by four common vaccine-preventable serogroups(1)

Central phone:

+41 61 324 7944

Ruth Metzler-Arnold

+41 61 324 9980

North America:

Pierre-Michel Bringer

+41 61 324 1065

Richard Jarvis

+1 212 830 2433

John Gilardi

+41 61 324 3018

Jill Pozarek

+1 212 830 2445

Thomas Hungerbuehler

+41 61 324 8425

Edwin Valeriano

+1 212 830 2456

Isabella Zinck

+41 61 324 7188

e-mail: [email protected]

e-mail: [email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook